[go: up one dir, main page]

AR020062A1 - Una composicion farmaceutica solida o semisolida para la liberacion sostenida de peptidos - Google Patents

Una composicion farmaceutica solida o semisolida para la liberacion sostenida de peptidos

Info

Publication number
AR020062A1
AR020062A1 ARP990101275A ARP990101275A AR020062A1 AR 020062 A1 AR020062 A1 AR 020062A1 AR P990101275 A ARP990101275 A AR P990101275A AR P990101275 A ARP990101275 A AR P990101275A AR 020062 A1 AR020062 A1 AR 020062A1
Authority
AR
Argentina
Prior art keywords
solid
pharmaceutical composition
peptides
sustained release
semisolid pharmaceutical
Prior art date
Application number
ARP990101275A
Other languages
English (en)
Original Assignee
Scient S C R A S Soc De Conseils De Rech S Et D Applic S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scient S C R A S Soc De Conseils De Rech S Et D Applic S filed Critical Scient S C R A S Soc De Conseils De Rech S Et D Applic S
Publication of AR020062A1 publication Critical patent/AR020062A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una composicion farmacéutica solida o semisolida que contiene una sal de péptido soluble gelificable de alta área específica superficial. Esta composiciontambién puede comprender un excipiente y/o agua. Una vez inyectada en un paciente, la composicion se gelifica y libera la sal de péptido durante un períodoprolongado de al menos 15 días.
ARP990101275A 1998-03-25 1999-03-23 Una composicion farmaceutica solida o semisolida para la liberacion sostenida de peptidos AR020062A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9803667A FR2776520B1 (fr) 1998-03-25 1998-03-25 Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation

Publications (1)

Publication Number Publication Date
AR020062A1 true AR020062A1 (es) 2002-04-10

Family

ID=9524472

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101275A AR020062A1 (es) 1998-03-25 1999-03-23 Una composicion farmaceutica solida o semisolida para la liberacion sostenida de peptidos

Country Status (19)

Country Link
US (1) US6503534B1 (es)
EP (1) EP1066049B1 (es)
JP (1) JP4162381B2 (es)
AR (1) AR020062A1 (es)
AT (1) ATE241377T1 (es)
AU (1) AU756148B2 (es)
CA (1) CA2324901C (es)
CZ (1) CZ298941B6 (es)
DE (1) DE69908326T2 (es)
DK (1) DK1066049T3 (es)
ES (1) ES2200507T3 (es)
FR (1) FR2776520B1 (es)
HU (1) HU228903B1 (es)
IL (2) IL138533A0 (es)
NO (1) NO324621B1 (es)
PL (1) PL197775B1 (es)
PT (1) PT1066049E (es)
RU (1) RU2224538C2 (es)
WO (1) WO1999048517A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
PL208073B1 (pl) * 2002-09-27 2011-03-31 Aeterna Zentaris Gmbh Żelowy preparat farmaceutyczny oraz sposób jego otrzymywania i zestaw do jego wytwarzania
RU2255760C2 (ru) * 2003-03-11 2005-07-10 Общество с ограниченной ответственностью фирма "Фермент" Средство, обладающее иммуномодулирующим, противомикробным, антиоксидантным и регенерирующим действием (варианты)
US20040247689A1 (en) * 2003-03-26 2004-12-09 Guy Samburski Process for preparing a pharmaceutical active ingredient with high specific surface area
PT1684782E (pt) 2003-10-03 2015-12-21 Thorn Bioscience Llc Processo para a sincronização da ovulação para reprodução regulada sem detecção do cio
EP1694278A4 (en) * 2003-12-16 2009-08-12 Ipsen Pharma GLP-1 PHARMACEUTICAL COMPOSITIONS
WO2005067890A2 (en) * 2004-01-13 2005-07-28 Vasogenix Pharmaceuticals, Inc. Controlled release cgrp delivery composition for cardiovascular and renal indications
EP1703916A2 (en) * 2004-01-13 2006-09-27 Vasogenix Pharmaceuticals, Inc. Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
US20090023644A1 (en) * 2004-01-13 2009-01-22 Southard Jeffery L Methods of using cgrp for cardiovascular and renal indications
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
GB0511269D0 (en) * 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
CN102160957A (zh) * 2005-07-28 2011-08-24 乞力马扎罗能量公司 从空气中除去二氧化碳
GB0517627D0 (en) 2005-08-30 2005-10-05 Tyco Electronics Ltd Uk Bus-bar and connector
US8841255B2 (en) * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP1971355B1 (en) 2005-12-20 2020-03-11 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20070219811A1 (en) * 2006-03-16 2007-09-20 Kim John S Method for using an internet-based CRM application to create an on-line leads marketplace
CA2671925A1 (en) * 2006-12-21 2008-07-10 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
EP2142207A4 (en) * 2007-04-04 2013-01-16 Theratechnologies Inc PHARMACEUTICAL FORMULATIONS OF GHRH MOLECULES
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
WO2009158704A2 (en) 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
PL2421545T3 (pl) 2009-04-23 2018-05-30 Jbs United Animal Health Ii Llc Sposób i kompozycja do synchronizacji czasu inseminacji
WO2010125468A1 (en) 2009-05-01 2010-11-04 Ferring International Center Sa Composition for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
PL3311828T3 (pl) * 2009-08-14 2021-11-22 Phasebio Pharmaceuticals, Inc. Zmodyfikowane wazoaktywne peptydy jelitowe
US9352012B2 (en) * 2010-01-13 2016-05-31 Ipsen Pharma S.A.S. Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
PT2632934T (pt) 2010-10-27 2017-01-06 Ferring Bv Processo para o fabrico de degarelix e seus intermediários
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2012170524A1 (en) 2011-06-06 2012-12-13 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
DE102011114864A1 (de) 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
CA2874927A1 (en) 2012-06-01 2013-12-05 Gregoire Schwach Manufacture of degarelix
JP2016508030A (ja) 2012-11-28 2016-03-17 ジェイビーエス ユナイテッド アニマル ヘルス セカンド エルエルシー 未経産ブタにおける授精の時期を同期化するための方法および組成物
EP2823808A1 (en) 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
EP2910255A1 (en) * 2014-02-19 2015-08-26 MedSkin Solutions Dr. Suwelack AG Methods for the production of biopolymers with defined average molecular weight
TW201625218A (zh) * 2014-04-18 2016-07-16 Ｊｂｓ聯合動物保健有限責任公司 製造含ｇｎｒｈ凝膠之方法
AU2015255752B2 (en) 2014-05-08 2020-07-23 Immunoforge Co., Ltd. Methods and compositions for treating Cystic Fibrosis
JP6824888B2 (ja) 2015-02-09 2021-02-03 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 筋肉の疾患および障害を治療するための方法および組成物
WO2020170185A1 (en) * 2019-02-21 2020-08-27 Dr. Reddy’S Laboratories Limited Substantially pure lanreotide or its salt & process thereof
GR1009814B (el) * 2019-07-29 2020-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει ενα πεπτιδιο αναλογο σωματοστατινης
CN110577567A (zh) * 2019-09-03 2019-12-17 杭州诺泰澳赛诺医药技术开发有限公司 一种制备高比表面积活性多肽或蛋白的方法
EP4436633A4 (en) * 2021-11-22 2025-10-08 SpecGx LLC INJECTABLE PHARMACEUTICAL COMPOSITION WITH EXTENDED RELEASE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2030551C (en) * 1989-05-01 1998-08-25 Wayne Gombotz Process for producing small particles of biologically active molecules
JP3100005B2 (ja) * 1992-07-28 2000-10-16 雪印乳業株式会社 ヒト免疫不全ウィルス感染・増殖抑制剤
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions

Also Published As

Publication number Publication date
PL197775B1 (pl) 2008-04-30
DE69908326T2 (de) 2004-03-25
WO1999048517A1 (fr) 1999-09-30
HUP0101545A1 (hu) 2001-11-28
FR2776520A1 (fr) 1999-10-01
IL138533A (en) 2006-12-31
RU2224538C2 (ru) 2004-02-27
ES2200507T3 (es) 2004-03-01
HUP0101545A3 (en) 2001-12-28
CZ298941B6 (cs) 2008-03-19
DK1066049T3 (da) 2003-09-29
CZ20003432A3 (cs) 2001-02-14
JP2002507578A (ja) 2002-03-12
DE69908326D1 (de) 2003-07-03
US6503534B1 (en) 2003-01-07
PL343005A1 (en) 2001-07-30
AU756148B2 (en) 2003-01-02
IL138533A0 (en) 2001-10-31
EP1066049A1 (fr) 2001-01-10
NO324621B1 (no) 2007-11-26
CA2324901C (fr) 2012-01-24
ATE241377T1 (de) 2003-06-15
NO20004741D0 (no) 2000-09-22
NO20004741L (no) 2000-11-22
JP4162381B2 (ja) 2008-10-08
EP1066049B1 (fr) 2003-05-28
AU2938499A (en) 1999-10-18
PT1066049E (pt) 2003-10-31
FR2776520B1 (fr) 2000-05-05
HU228903B1 (en) 2013-06-28
CA2324901A1 (fr) 1999-09-30

Similar Documents

Publication Publication Date Title
AR020062A1 (es) Una composicion farmaceutica solida o semisolida para la liberacion sostenida de peptidos
ES2050070B1 (es) Procedimiento para la preparacion de una composicion destinada a la liberacion prolongada y controlada de una substancia peptidica.
HUP0301842A2 (hu) Laktám vegyület, a vegyületet tartalmazó gyógyszerkészítmény és alkalmazása gyógyszerkészítmény elżállítására
GT199800126A (es) Terapia de combinacion.
ES8706169A1 (es) Procedimiento para preparar peptidos trifluormetilcetona-sustituidos.
ES2107041T3 (es) Variantes de activador de plasminogeno tisular obtenidos por glicosilacion, que presentan propiedades terapeuticas.
TR199902071T2 (xx) Heterosiklik bile�ikler ve bunlar�n �-amilioid peptidinin inhibisyonunda kullan�m�
BR9406720A (pt) Utilização de um adenovírus recombinante de origem animal adenovírus recombinante de origem animal e composição farmacêutica compreendendo um ou vários adenovírus
ES2151079T3 (es) Preparacion de liberacion sostenida que contiene una sal metalica de un peptido.
LTC1131065I2 (lt) Dialkilfumaratai, skirti autoimuninėms ligoms gydyti
DE69740096D1 (de) Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid
DK0839026T3 (da) Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
BR9811094A (pt) Agente terapêutico para tumores linfáticos
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
SE9402880D0 (sv) New peptide derivatives
FR2696925B3 (fr) Nécessaire de chirurgie orthopédique destiné à réaliser l'ancrage de la partie osseuse d'un ligament dans un tunnel osseux.
UY27373A1 (es) Formulaciones de interferón beta-humano
ES2157221T3 (es) Composiciones metaloporfirinicas.
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
ATE283706T1 (de) ßGEGEN RACEMISIERUNG STABILISIERTE PHARMAZEUTISCHE ZUBEREITUNGEN VON CILANSETRONß
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
GT199900171A (es) Concentrado oral de sertralina.
BR0008385A (pt) Laxantes efervescentes

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FC Refusal